Dear Sir, Please find attached News paper publication of Audited results of Quarter and year ended on 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd has submitted the newspaper publication of its audited standalone financial results for the quarter and year ended 31 March 2025, as required under SEBI listing regulations. Total income from operations stood at Rs. 13.50 lakh for Q4 FY25 and Rs. 54.00 lakh for the full year FY25, largely flat compared to the previous year. Net profit after tax improved to Rs. 20.09 lakh in FY25 from Rs. 18.91 lakh in FY24, while Q4 FY25 showed a small loss of Rs. 2.15 lakh. Basic and diluted EPS rose marginally to Rs. 0.20 in FY25 from Rs. 0.19 in FY24. Equity share capital remained unchanged at Rs. 1,008.37 lakh. The results were reviewed by the audit committee and approved by the board on 28 May 2025.
The results indicate very modest scale of operations with stagnant revenue but slightly improved bottom line for retail shareholders. The small absolute numbers suggest limited business activity, so this publication is primarily a routine regulatory filing rather than a material event for the stock.